Aktienanalyse zu Acumen Pharmaceuticals Inc (ABOS)ABOSAcumen Pharmaceuticals Inc

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The Company is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Acumen Pharmaceuticals Inc is a good buy right now due to its current price of $2.14, which is significantly below the analyst price target of $5, indicating a potential upside of over 134%. Additionally, the company has shown a reduced net loss of $32.72 million in Q2 2026 compared to $40.95 million in the same quarter last year, reflecting improved financial management. However, the main risk is the ongoing negative earnings per share (EPS) trend, with a reported EPS of -0.45 for Q2 2026, which could affect investor sentiment if not reversed.